Detailed Strategic Options for Novo Nordisk
[pic]
MBA企业调研报告
MBA Business Research Report
标题：诺和诺德制药有限公司在中国的战略分析
Title：Analysis of Novo Nordisk Pharmaceuticals Company’s Strategy in China
姓名Name ：陈剑锋 （CHEN Jianfeng）
学号ID Number ：20092711001
指导老师 Supervisor ：杨晓燕
Guangdong University of Foreign Studies
2010年10月08日
教师评语及分数 Tutor’s Comments and Grade
签名 signature 时间 Date 2010-
Abstract
In this case report we will try to analysis the detailed strategic options for Novo Nordisk as a top human Insulin provider to sustain its growth internationally. We will give comments for our recommendations and evaluate the VRIO Framework of the internal organization and provide a clear Five Forces Analysis.
Novo Nordisk is a Denmark based Bio-Pharmaceuticals giant that has been one of key company which shaping diabetes care industry was known by health care professional Novo Nordisk has occupied one third European and Latin America insulin markets. The company now has high ambitious to enter into Asian market especially China Market in the coming five years.
We have developed one strategy base on its Marketing strategy and China actual diabetes healthcare situation for management to consider. We divided Our strategy into two parts, one is maintain the leading position in Insulin market ( Novo Nordisk ), another is to expand the market share of oral anti-diabetes. Follow the strategy we will suggest NN should segment the Market into different tier of cities within China, at the same time NN may need to differentiate the strategy of Insulin with oral anti-diabetes drug.
Key words： Novo Nordisk Strategy Diabetes Pharmaceuticals
Table of Contents:
1. ………………………………………………………………………….. Abstract
2. ,,,,,……………………………………………………….Mission & Objectives
3. ..........................................................................................NN strategic objective 3.1…………………………………………Integrative insulin treatment line
MBA企业调研报告
MBA Business Research Report
标题：诺和诺德制药有限公司在中国的战略分析
Title：Analysis of Novo Nordisk Pharmaceuticals Company’s Strategy in China
姓名Name ：陈剑锋 （CHEN Jianfeng）
学号ID Number ：20092711001
指导老师 Supervisor ：杨晓燕
Guangdong University of Foreign Studies
2010年10月08日
教师评语及分数 Tutor’s Comments and Grade
签名 signature 时间 Date 2010-
Abstract
In this case report we will try to analysis the detailed strategic options for Novo Nordisk as a top human Insulin provider to sustain its growth internationally. We will give comments for our recommendations and evaluate the VRIO Framework of the internal organization and provide a clear Five Forces Analysis.
Novo Nordisk is a Denmark based Bio-Pharmaceuticals giant that has been one of key company which shaping diabetes care industry was known by health care professional Novo Nordisk has occupied one third European and Latin America insulin markets. The company now has high ambitious to enter into Asian market especially China Market in the coming five years.
We have developed one strategy base on its Marketing strategy and China actual diabetes healthcare situation for management to consider. We divided Our strategy into two parts, one is maintain the leading position in Insulin market ( Novo Nordisk ), another is to expand the market share of oral anti-diabetes. Follow the strategy we will suggest NN should segment the Market into different tier of cities within China, at the same time NN may need to differentiate the strategy of Insulin with oral anti-diabetes drug.
Key words： Novo Nordisk Strategy Diabetes Pharmaceuticals
Table of Contents:
1. ………………………………………………………………………….. Abstract
2. ,,,,,……………………………………………………….Mission & Objectives
3. ..........................................................................................NN strategic objective 3.1…………………………………………Integrative insulin treatment line